Wnt信号调节因子DKK1作为卵巢癌免疫治疗靶点的研究
研究探讨DKK1在卵巢癌中的作用及抗DKK1单克隆抗体DKN-01的体内外效果。体外DKN-01未改变ES2细胞表型但抑制DKK1促进Wnt信号;ID8小鼠模型中DKN-01未改变肿瘤负荷和免疫细胞群,但DKK1过表达降低腹腔和网膜CD45+白细胞浸润及NK、CD8 T细胞和活化CD8 T细胞IFNγ表达。结论提示DKK1抑制在ID8模型中不影响肿瘤生长,DKK1过表达改变肿瘤微环境抗肿瘤免疫细胞群。
要点
- DKN-01体外未改变ES2细胞表型,但DKK1抑制促进Wnt信号。
- ID8小鼠中DKN-01未改变肿瘤负荷和免疫细胞群。
- DKK1过表达降低腹腔和网膜CD45+白细胞、NK及CD8 T细胞浸润。
核心结论
- DKK1抑制在ID8卵巢癌模型中不影响肿瘤生长。
- DKK1过表达改变肿瘤微环境中的抗肿瘤免疫细胞群。
- DKK1抑制可能最适合与免疫调节治疗联合应用。
研究设计与样本
- 体外研究EOC细胞系中DKK1的作用及DKK1抑制效果。
- 体内使用ID8同系小鼠模型研究DKN-01和DKK1过表达对肿瘤负荷及抗肿瘤免疫细胞群的影响。
主要发现
- DKN-01体外未改变ES2细胞表型,但DKK1抑制促进Wnt信号。
- mDKN01治疗的ID8小鼠肿瘤负荷和免疫细胞群未改变。
- DKK1过表达组肿瘤负荷与对照组相似(p = 0.175)。
- DKK1过表达降低腹腔CD45+白细胞浸润(p = 0.008)和网膜CD45+白细胞浸润(p = 0.032)。
- DKK1过表达减少NK细胞和CD8 T细胞,降低活化CD8 T细胞IFNγ表达。
临床怎么用
- DKK1抑制单药在ID8模型中未显示肿瘤生长抑制作用。
- DKK1过表达与免疫抑制微环境相关,支持联合免疫调节治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Wnt pathway mutations are a hallmark of endometrioid and clear cell subtypes of epithelial ovarian carcinoma (EOC). However, no drugs targeting the Wnt pathway in EOC are FDA-approved. Dickkopf-related protein 1 (DKK1), a modulator of the Wnt pathway, has emerged as a promising therapeutic target. We aimed to examine the role of DKK1 and the effects of a monoclonal antibody against DKK1 (DKN-01) in vivo and in a murine model of ovarian cancer. METHODS: We examined in vitro the role of DKK1 and the effects of DKK1 inhibition in EOC cell lines. We then studied in vivo the role of DKN-01 and DKK1 overexpression on tumor burden and anti-tumor immune cell populations using the ID8 syngeneic mouse model. RESULTS: DKN-01 did not phenotypically alter ES2 cells in vitro; however, DKK1 inhibition promoted Wnt signaling. Tumor burden and immune populations were unchanged in ID8 challenged mice treated with mDKN01. Mice challenged with ID8 cells overexpressing DKK1 had tumor burden similar to controls (p = 0.175). However, the overexpression of DKK1 decreased CD45+ leukocyte infiltration into the peritoneum (p = 0.008) and omentum (p = 0.032), reducing both natural killer (NK) and CD8 T cells, and reducing interferon-gamma (IFNγ) expression on activated CD8 T cells. CONCLUSIONS: Our results suggest that DKK1 inhibition does not affect tumor growth in the ID8 ovarian cancer model. DKK1 overexpression alters anti-tumor immune populations within the tumor microenvironment. Thus, our findings confirm DKK1 as a new therapeutic target in EOC and suggest that DKK1 inhibition may function best in a combinatorial, immune-modulatory therapy.
引用
- Betella I, Turbitt WJ, Szul T, et al. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. Gynecol Oncol. 2020. PMID: 32192732. doi:10.1016/j.ygyno.2020.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。